Eculizumab vs Pozelimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Generalized Myasthenia Gravis
Shared mechanism: Complement C5 · full Generalized Myasthenia Gravis pipeline
Eculizumab · Soliris
Marketed by AstraZeneca
NCT01997229 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 125 patients with a clinical primary endpoint, the MG-ADL daily-living score. The primary comparison was not statistically significant (difference in mean rank -11.7, 95% CI -24.33 to 0.96, p=0.0698), so the trial does not provide strong evidence of benefit despite its sound design.
Reported efficacy
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) (missed)
Result source: NCT01997229
Pozelimab · Veopoz
Marketed by Regeneron Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Generalized Myasthenia Gravis
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Pozelimab: no structured comparison results are available for Generalized Myasthenia Gravis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Paroxysmal Nocturnal Hemoglobinuria
Shared mechanism: Complement C5 · full Paroxysmal Nocturnal Hemoglobinuria pipeline
Eculizumab · Soliris
Marketed by AstraZeneca
NCT00122317 · Phase 3 · completed
This was a single-arm, open-label extension of participants from the prior TRIUMPH, SHEPHERD, or X03-001 studies, with 187 participants and no placebo or active comparator. Its primary endpoint measured treatment-emergent adverse events rather than comparative clinical efficacy, so the findings provide limited evidence about eculizumab’s effectiveness. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: May 2027 · NCT06449001 (registry estimate)
Reported efficacy
Incidence of Treatment-emergent Adverse Events (From time of consent to a maximum of 2.5 years of study treatment): Incidence of Treatment-emergent Adverse Events (From time of consent to a maximum of 2.5 years of study treatment): Eculizumab 182 Participants (not_applicable)
Result source: NCT00122317
Pozelimab · Veopoz
Marketed by Regeneron Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2028 · NCT05744921 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Paroxysmal Nocturnal Hemoglobinuria
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Eculizumab: registry results are on file for Paroxysmal Nocturnal Hemoglobinuria, but their comparison mappings are not yet available.
Pozelimab: no structured comparison results are available for Paroxysmal Nocturnal Hemoglobinuria.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eculizumab's landscape · Pozelimab's landscape